Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3285MR)

This product GTTS-WQ3285MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3285MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11020MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ57MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ7150MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ1326MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ2660MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ2755MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ15837MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ10208MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW